المؤلفون: Werth VP; Department of Dermatology, Penn Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Dermatology Division, Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA. Electronic address: werth@pennmedicine.upenn.edu., Culton DA; Department of Dermatology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Concha JSS; Department of Dermatology, Penn Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Dermatology Division, Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA., Graydon JS; Alexion Pharmaceuticals, Inc, Boston, Massachusetts, USA; Syntimmune, Boston, Massachusetts, USA., Blumberg LJ; Syntimmune, Boston, Massachusetts, USA., Okawa J; Department of Dermatology, Penn Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Dermatology Division, Corporal Michael J. Crescenz VAMC, Philadelphia, Pennsylvania, USA., Pyzik M; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Blumberg RS; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Hall RP 3rd; Department of Dermatology, Duke University Medical Center, Durham, North Carolina, USA.

المصدر: The Journal of investigative dermatology [J Invest Dermatol] 2021 Dec; Vol. 141 (12), pp. 2858-2865.e4. Date of Electronic Publication: 2021 Jun 12.

نوع المنشور: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 0426720 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-1747 (Electronic) Linking ISSN: 0022202X NLM ISO Abbreviation: J Invest Dermatol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Immunoglobulin G/*therapeutic use , Pemphigus/*drug therapy , Receptors, Fc/*antagonists & inhibitors, Adolescent ; Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacokinetics ; Autoantibodies/blood ; Chronic Disease ; Female ; Histocompatibility Antigens Class I ; Humans ; Immunoglobulin G/adverse effects ; Male ; Middle Aged ; Pemphigus/immunology ; Young Adult